JP2017518075A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518075A5
JP2017518075A5 JP2017515025A JP2017515025A JP2017518075A5 JP 2017518075 A5 JP2017518075 A5 JP 2017518075A5 JP 2017515025 A JP2017515025 A JP 2017515025A JP 2017515025 A JP2017515025 A JP 2017515025A JP 2017518075 A5 JP2017518075 A5 JP 2017518075A5
Authority
JP
Japan
Prior art keywords
nucleic acid
composition
virus
hbv
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/033180 external-priority patent/WO2015184259A1/en
Publication of JP2017518075A publication Critical patent/JP2017518075A/ja
Publication of JP2017518075A5 publication Critical patent/JP2017518075A5/ja
Pending legal-status Critical Current

Links

JP2017515025A 2014-05-30 2015-05-29 潜伏性ウイルス感染を処置するための組成物および方法 Pending JP2017518075A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462005395P 2014-05-30 2014-05-30
US62/005,395 2014-05-30
US201462029072P 2014-07-25 2014-07-25
US62/029,072 2014-07-25
PCT/US2015/033180 WO2015184259A1 (en) 2014-05-30 2015-05-29 Compositions and methods to treat latent viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019205922A Division JP2020043862A (ja) 2014-05-30 2019-11-14 潜伏性ウイルス感染を処置するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2017518075A JP2017518075A (ja) 2017-07-06
JP2017518075A5 true JP2017518075A5 (https=) 2018-07-05

Family

ID=53366336

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515026A Pending JP2017518372A (ja) 2014-05-30 2015-05-29 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法
JP2017515025A Pending JP2017518075A (ja) 2014-05-30 2015-05-29 潜伏性ウイルス感染を処置するための組成物および方法
JP2019205922A Pending JP2020043862A (ja) 2014-05-30 2019-11-14 潜伏性ウイルス感染を処置するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017515026A Pending JP2017518372A (ja) 2014-05-30 2015-05-29 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019205922A Pending JP2020043862A (ja) 2014-05-30 2019-11-14 潜伏性ウイルス感染を処置するための組成物および方法

Country Status (10)

Country Link
US (7) US20160060655A1 (https=)
EP (3) EP3149169A1 (https=)
JP (3) JP2017518372A (https=)
KR (1) KR20170005494A (https=)
CN (2) CN107002094A (https=)
AU (3) AU2015266767A1 (https=)
BR (1) BR112016028023A2 (https=)
CA (2) CA2949710A1 (https=)
SG (1) SG11201610028TA (https=)
WO (3) WO2015184259A1 (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
JP7118588B2 (ja) 2013-08-29 2022-08-16 テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Hiv感染のrnaガイド処置のための方法および組成物
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015184259A1 (en) 2014-05-30 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
KR102531016B1 (ko) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
US10059940B2 (en) * 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
EP3331582A4 (en) * 2015-05-29 2019-08-07 Agenovir Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
US20160346362A1 (en) * 2015-05-29 2016-12-01 Agenovir Corporation Methods and compositions for treating cytomegalovirus infections
WO2016196282A1 (en) * 2015-05-29 2016-12-08 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
JP2018532403A (ja) * 2015-09-29 2018-11-08 アジェノビア コーポレーション 送達方法および組成物
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
AU2016366229A1 (en) 2015-12-09 2018-05-17 Excision Biotherapeutics, Inc. Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
JP2019512458A (ja) * 2016-01-25 2019-05-16 エクシジョン バイオセラピューティクス インコーポレイテッド Rnaによって誘導された、ヒトjcウイルス及び他のポリオーマウイルスの根絶
JP2019506156A (ja) * 2016-01-25 2019-03-07 エクシジョン バイオセラピューティクス インコーポレイテッド Hiv感染症のrna誘導型治療のための方法及び組成物
EP3420077A4 (en) * 2016-02-25 2019-12-25 Agenovir Corporation VIRAL AND ONCOVIRAL NUCLEASE TREATMENT
US20170246260A1 (en) * 2016-02-25 2017-08-31 Agenovir Corporation Modified antiviral nuclease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US20190093092A1 (en) * 2016-05-05 2019-03-28 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of varicella zoster virus
JP2019519250A (ja) * 2016-05-10 2019-07-11 ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズUnited States Government As Represented By The Department Of Veterans Affairs Hiv−1感染と複製に必須な遺伝子を切断するcrispr/casの構築物のレンチウィルスによる送達
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
WO2017210380A1 (en) * 2016-06-01 2017-12-07 Excision Biotherapeutics, Inc. Compositions and methods of treatment for lytic and lysogenic viruses
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
KR20230110373A (ko) * 2016-06-14 2023-07-21 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직,및 장기
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11801374B2 (en) * 2016-09-02 2023-10-31 The General Hospital Corporation Methods and systems for non-contact construction of an internal structure
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
WO2018112225A1 (en) * 2016-12-14 2018-06-21 The J. David Gladstone Institutes Methods and compositions for generating a deletion library and for identifying a defective interfering particle (dip)
CN106729753A (zh) * 2016-12-16 2017-05-31 谭旭 抗乙型肝炎病毒的递送系统和生物制剂
WO2018118587A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Modified polynucleotides for antiviral therapy
WO2018118586A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Antiviral/endogenous combination therapy
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018136396A2 (en) * 2017-01-18 2018-07-26 Excision Biotherapeutics, Inc. Crisprs
US20190071673A1 (en) * 2017-01-18 2019-03-07 Thomas Malcolm CRISPRs WITH IMPROVED SPECIFICITY
CN110431230A (zh) * 2017-01-26 2019-11-08 切除生物治疗公司 慢病毒和非整合型慢病毒作为病毒载体实施crispr治疗
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN118581154A (zh) * 2017-06-02 2024-09-03 国家健康与医学研究院 用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
AU2018320849A1 (en) * 2017-08-25 2020-03-05 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
JP7399876B2 (ja) * 2018-04-16 2023-12-18 ジョージア テック リサーチ コーポレーション 病態治療のためのRNAエディターのmRNA駆動型発現
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN109943563A (zh) * 2019-03-08 2019-06-28 内蒙古大学 CRISPR-Cas9系统介导的狂犬病病毒基因组敲除的方法
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12614611B2 (en) * 2019-06-06 2026-04-28 Tata Consultancy Services Limited Method and system for identification of candidate target sites for combating pathogens
CN112168808B (zh) * 2019-07-02 2023-01-24 深圳市第二人民医院 一种基于crispr的细胞核靶向药物递送系统
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CN112795696A (zh) * 2020-12-31 2021-05-14 北京思尔成生物技术有限公司 乙型肝炎病毒pgRNA芯片数字PCR绝对定量检测试剂盒及方法
WO2022261149A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドrna
CN114196556B (zh) * 2021-12-31 2023-08-01 重庆大学 一种高毒力蝗绿僵菌菌株及其构建方法
CN117065052A (zh) * 2022-05-16 2023-11-17 上海行深生物科技有限公司 递送自复制rna分子的方法
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003131A (en) * 1910-08-17 1911-09-12 Leonard F Bellingrath Valve operating and indicating mechanism.
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5580571A (en) 1991-10-15 1996-12-03 Hostetler; Karl Y. Nucleoside analogues
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
EP0642589A4 (en) * 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
EP1624068A1 (en) 1993-06-01 2006-02-08 Life Technologies Inc. Genetic immunization with cationic lipids
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2003514871A (ja) * 1999-11-24 2003-04-22 オクラホマ メディカル リサーチ ファウンデーション 潜伏ウイルス感染についてのアッセイおよび治療
US7740871B2 (en) * 2002-09-19 2010-06-22 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
CN1920562A (zh) * 2003-08-20 2007-02-28 香港神农有限公司 Eb病毒蛋白酶联免疫吸附诊断试剂盒及其制备方法
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
EP1844136B1 (en) 2004-12-29 2014-08-27 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
ES2582091T3 (es) * 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
AU2006338570B2 (en) 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
EP2027262B1 (en) 2006-05-25 2010-03-31 Sangamo Biosciences Inc. Variant foki cleavage half-domains
WO2009024834A2 (en) * 2006-12-05 2009-02-26 Rosetta Genomics Ltd Nucleic acids involved in viral infection
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US20110023144A1 (en) 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
CN101880649B (zh) 2009-05-05 2012-09-05 中国福利会国际和平妇幼保健院 一种干细胞培养方法
WO2011119628A2 (en) * 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
CN103361328B (zh) * 2012-03-30 2017-08-18 复旦大学 介导整合的hiv‑1前病毒基因敲除的锌指核酸内切酶及其制法和应用
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
US20150315576A1 (en) 2012-11-01 2015-11-05 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
IL239344B2 (en) 2012-12-12 2024-06-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3031921B1 (en) * 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
WO2014143381A1 (en) 2013-03-09 2014-09-18 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
RU2662932C2 (ru) 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CA2908253C (en) 2013-04-04 2024-01-09 Trustees Of Dartmouth College Compositions and methods for in vivo excision of hiv-1 proviral dna
US20160186208A1 (en) 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
ES2929143T3 (es) 2013-07-09 2022-11-25 Harvard College Ingeniería genómica guiada por ARN múltiplex
JP6482546B2 (ja) 2013-07-19 2019-03-13 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーLarix Bioscience, Llc 二重対立遺伝子ノックアウトを生成するための方法および組成物
JP7118588B2 (ja) 2013-08-29 2022-08-16 テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Hiv感染のrnaガイド処置のための方法および組成物
EP4074330A1 (en) 2013-09-05 2022-10-19 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
SG10201804975PA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
EP3083958B1 (en) 2013-12-19 2019-04-17 Amyris, Inc. Methods for genomic integration
US10286084B2 (en) 2014-02-18 2019-05-14 Duke University Compositions for the inactivation of virus replication and methods of making and using the same
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
CN103911376B (zh) * 2014-04-03 2017-02-15 黄行许 CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA
WO2015184259A1 (en) 2014-05-30 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections

Similar Documents

Publication Publication Date Title
JP2017518075A5 (https=)
JP2017518372A5 (https=)
JP2018516984A5 (https=)
JP2018516983A5 (https=)
JP7176737B2 (ja) レトロウイルス核酸配列の切除
JP2020043862A (ja) 潜伏性ウイルス感染を処置するための組成物および方法
AU2016270702B2 (en) Methods and compositions for RNA-guided treatment of HIV infection
Vannucci et al. Viral vectors: a look back and ahead on gene transfer technology
RU2018124657A (ru) Способы редактирования генов и композиции для устранения риска активации вируса jc и пмл (прогрессирующая мультифокальная лейкоэнцефалопатия) во время иммуносупрессивной терапии
JP2018532403A5 (https=)
JP2018516983A (ja) ウイルス感染を処置するための組成物および方法
Sun et al. Advances in therapeutic application of CRISPR-Cas9
Herskovitz et al. Pathways toward a functional HIV-1 cure: Balancing promise and perils of CRISPR therapy
Small et al. The effect of adenovirus-specific antibodies on adenoviral vector–induced, transgene product–specific T cell responses
CN108103094B (zh) 用于靶向抑制hiv-1前病毒表达的表达载体及其制备方法和应用
WO2013037841A3 (fr) Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1
Shoji et al. Type-I IFN signaling is required for the induction of antigen-specific CD8+ T cell responses by adenovirus vector vaccine in the gut-mucosa
Solanki et al. CRISPR-Cas based genome editing for eradication of human viruses
Kundu et al. Developing New Molecular-Targeted Therapeutics,‘from Gene to Drug'
Khudhur Utilizing CRISPR Technology to Develop Vaccinations and Treatments Against Viruses
Mayes CRISPR Technology as an Antiviral in dsDNA and ssRNA Viruses
Pattacini The perils of cutting what you cannot see